Molecular Partners Ag (MOLN) Receivables - Net (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Receivables - Net of $2953.7 for Q1 2026, down 33.23% year-on-year from $4423.4 in Q1 2025, and up 28.72% on a QoQ basis from $2294.6 in Q4 2025.
Molecular Partners Ag (MOLN) Receivables - Net (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Receivables - Net for 7 consecutive years, with $2953.7 the latest figure, recorded in Q1 2026.
- Quarterly Receivables - Net fell 33.23% year-over-year to $2953.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2953.7 (down 33.23% YoY) and the FY2025 annual result came in at $2.3 million, down 13.24% from the prior year.
- Receivables - Net improved to $2953.7 in Q1 2026 per MOLN's latest filing, from $2294.6 in the prior quarter.
- Over the last five years, Receivables - Net for MOLN reached as high as $20.7 million in Q2 2023 and fell as low as $1791.3 in Q3 2022.
- A 5-year average of $3.9 million and a median of $3829.7 in 2024 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2023 — Receivables - Net surged 108.15% — and 2025, when it tumbled 99.98%.
- Year by year, Receivables - Net stood at $1.1 million in 2022, then jumped by 108.15% to $2.2 million in 2023, then climbed by 20.13% to $2.6 million in 2024, then slumped by 99.91% to $2294.6 in 2025, then increased by 28.72% to $2953.7 in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $2953.7, $2294.6, and $2629.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,953.71 |
| Mar 31, 2026 | 2,953.71 |
| Dec 31, 2025 | 2,294.65 |
| Dec 31, 2025 | 2,294.65 |
| Sep 30, 2025 | 2,628.98 |
| Sep 30, 2025 | 2,628.98 |
| Jun 30, 2025 | 4,354.44 |
| Jun 30, 2025 | 4,354.44 |
| Mar 31, 2025 | 4,423.42 |
| Mar 31, 2025 | 4,423.42 |
| Dec 31, 2024 | 2.64 Mn |
| Dec 31, 2024 | 2.64 Mn |
| Sep 30, 2024 | 3,829.66 |
| Sep 30, 2024 | 3,829.66 |
| Jun 30, 2024 | 20.57 Mn |
| Jun 30, 2024 | 20.57 Mn |
| Mar 31, 2024 | 3,642.12 |
| Mar 31, 2024 | 3,642.12 |
| Dec 31, 2023 | 2.20 Mn |
| Dec 31, 2023 | 2.20 Mn |